CIP
MYGN icon

Convergence Investment Partners’s Myriad Genetics MYGN Stock Holding History

Convergence Investment Partners’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-11,286
Closed -$519K – 347
2018
Q3 		$519K Sell
11,286
-28,177
-71% -$1.25M 0.11% 214
2018
Q2 		$1.48M Sell
39,463
-84,264
-68% -$2.85M 0.21% 145
2018
Q1 		$3.66M Buy
123,727
+13,450
+12% +$455K 0.48% 67
2017
Q4 		$3.79M Buy
+110,277
New +$3.72M 0.51% 65
2017
Q3 		– Sell
-59,770
Closed -$1.54M – 373
2017
Q2 		$1.54M Sell
59,770
-18,808
-24% -$399K 0.23% 176
2017
Q1 		$1.51M Buy
78,578
+62,200
+380% +$1.1M 0.21% 185
2016
Q4 		$273K Sell
16,378
-103,813
-86% -$1.88M 0.04% 291
2016
Q3 		$2.47M Buy
120,191
+13,064
+12% +$331K 0.37% 94
2016
Q2 		$3.28M Buy
107,127
+55,941
+109% +$1.94M 0.45% 78
2016
Q1 		$1.92M Sell
51,186
-74,978
-59% -$2.83M 0.23% 155
2015
Q4 		$5.45M Buy
+126,164
New +$5.33M 0.61% 31
2015
Q1 		– Sell
-47,424
Closed -$1.61M – 395
2014
Q4 		$1.61M Sell
47,424
-21,668
-31% -$769K 0.22% 163
2014
Q3 		$2.67M Hold
69,092
– – 0.37% 97
2014
Q2 		$2.69M Buy
69,092
+18,280
+36% +$680K 0.35% 97
2014
Q1 		$1.74M Sell
50,812
-73,791
-59% -$2.29M 0.26% 126
2013
Q4 		$2.61M Buy
124,603
+38,204
+44% +$966K 0.42% 73
2013
Q3 		$2.03M Buy
86,399
+26,351
+44% +$749K 0.43% 90
2013
Q2 		$1.61M Buy
+60,048
New +$1.74M 0.42% 89

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Convergence Investment Partners's MYGN Position: Q4 2018 in Review

Convergence Investment Partners sold out of Myriad Genetics (MYGN) in Q4 2018, closing a stake of 11,286 shares — an estimated $519K sold.

Convergence Investment Partners first reported a position in MYGN in Q2 2013 and held it in 18 quarters. The position peaked at $5.45M in Q4 2015. 264 funds tracked by Wall St. Rank hold MYGN as of Q4 2018.

  • Convergence Investment Partners reported no remaining Myriad Genetics position as of Q4 2018 after selling out during the quarter.
  • Convergence Investment Partners sold 11,286 Myriad Genetics shares in Q4 2018, an estimated $519K.
  • Convergence Investment Partners first reported a position in Myriad Genetics in Q2 2013 and held it in 18 quarters.
  • Convergence Investment Partners's Myriad Genetics position peaked at $5.45M in Q4 2015.
  • 264 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2018.

Based on Convergence Investment Partners's 13F filing for Q4 2018, filed 13 Feb 2019.